Cat. No. 3543
Alternative Name: IPD 1151T
Chemical Name: [3-[[4-(3-Ethoxy-2-hydroxypropoxy)p
Biological ActivityTh2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production. Acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Furonaka et al (2009) Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice. J.Pharmacol.Exp.Ther. 328 55. PMID: 18832650.
Hsu et al (2007) The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells. Transpl.Immunol. 18 108. PMID: 18005853.
Kurokawa et al (2001) Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 10 333. PMID: 11817674.
If you know of a relevant reference for Suplatast tosylate please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Suplatast tosylate from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Suplatast tosylate, supplier, Th2, cytokine, synthesis, inhibitors, inhibits, antiasthmatic, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, IPD1151T, Tocris Bioscience, Cytokine products
Find multiple products by catalog number
New Products in this Area
Receptor for advanced glycation end products (RAGE) antagonistGaliellalactone
STAT3 inhibitor; active in vivoCP 424174
Inhibitor of IL-1β post-translational processing; indirectly inhibits NLRP3IT 901
NF-κB c-Rel subunit inhibitor
August 20 - 24, 2017
Paris , France